Market closed
Ionis Pharmaceuticals/$IONS
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Ionis Pharmaceuticals
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024.
Ticker
$IONS
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
927
Website
IONS Metrics
BasicAdvanced
$5.7B
Market cap
-
P/E ratio
-$2.46
EPS
0.35
Beta
-
Dividend rate
Price and volume
Market cap
$5.7B
Beta
0.35
52-week high
$54.44
52-week low
$33.33
Average daily volume
1.6M
Financial strength
Current ratio
8.911
Quick ratio
8.238
Long term debt to equity
293.202
Total debt to equity
327.644
Interest coverage (TTM)
-3.87%
Management effectiveness
Return on assets (TTM)
-7.24%
Return on equity (TTM)
-73.42%
Valuation
Price to revenue (TTM)
6.526
Price to book
8.55
Price to tangible book (TTM)
8.55
Price to free cash flow (TTM)
-14.007
Growth
Revenue change (TTM)
30.60%
Earnings per share change (TTM)
-14.26%
3-year revenue growth (CAGR)
6.73%
3-year earnings per share growth (CAGR)
-17.14%
What the Analysts think about IONS
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Ionis Pharmaceuticals stock.
IONS Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
IONS Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
IONS News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Ionis Pharmaceuticals stock?
Ionis Pharmaceuticals (IONS) has a market cap of $5.7B as of December 31, 2024.
What is the P/E ratio for Ionis Pharmaceuticals stock?
The price to earnings (P/E) ratio for Ionis Pharmaceuticals (IONS) stock is 0 as of December 31, 2024.
Does Ionis Pharmaceuticals stock pay dividends?
No, Ionis Pharmaceuticals (IONS) stock does not pay dividends to its shareholders as of December 31, 2024.
When is the next Ionis Pharmaceuticals dividend payment date?
Ionis Pharmaceuticals (IONS) stock does not pay dividends to its shareholders.
What is the beta indicator for Ionis Pharmaceuticals?
Ionis Pharmaceuticals (IONS) has a beta rating of 0.35. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.